Clinical trial · Observational
Osimertinib for NSCLC With Uncommon EGFR Mutations
Uncommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-life Practice in First Line Setting
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Result summarized and published
Summary
Brief summary (as posted)
This is a multi-center, retrospective study of ucEGFRmut (exon 20 insertions excluded) metastatic NSCLC osimertinib-treated as first EGFR inhibitor. RECIST and RANO-BM brain objective response rate (ORR) were evaluated by investigators. mPFS, mOS and mDOR were calculated from osimertinib initiation. Mutations found at resistance were collected.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Genes, erbB-1 | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Osimertinib | Drug | Osimertinib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Progression free survival
- timeFrame
- From date of osimertinib initiation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
- description
- investigator-defined PFS
- measure
- Overall survival
- timeFrame
- From date of osimertinib initiation until date of death from any cause, assessed up to 100 months
- description
- OS
Secondary outcomes (6)
- measure
- Overall response rate
- timeFrame
- From date of osimertinib initiation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
- description
- RECIST-defined ORR
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years 2. NSCLC by histologic or cytologic diagnosis 3. Stage IV or stage III not amendable to curative treatment (i.e., advanced disease) 4. Uncommon mutation of EGFR (exon 20 insertion excluded) 5. Treated with osimertinib for advanced disease as first TKI 6. Osimertinib initiated not later than end of January 2021 Exclusion criteria: 1. Lack of any follow-up data 2. Lack of consent for data collection or ethics committee approval for the waiver of informed consent (i.e. for deceased patients)
References
Publications (0)
Data not yet available